Figure 1
From: Stimulation of alpha2-adrenergic receptors impairs influenza virus infection
Screening for novel influenza virus replication inhibitors. (A) Effect of screened compounds on influenza virus replication. AX4/PB2 cells were treated with the indicated compound (1 µM each) and subjected to a virus replication assay with Rluc. Each compound was tested in duplicate assay wells. (B) Effect of screened compounds on influenza vRNA transcription/replication activity. 293vRNP-Puro cells were cultured with the indicated compound (10 µM each) in the presence of puromycin, and vRNA transcription/replication activity was assessed by cell viability. Each compound was tested in duplicate assay wells. (C) Reproducibility of virus replication inhibition and cytotoxicity of the identified compounds. AX4/PB2 cells treated with various concentrations of the indicated compounds were subjected to a virus replication assay with Rluc and a cell viability assay. Each experiment includes data from duplicate assay wells. (D) Effect of clonidine on influenza virus replication. AX4/PB2 cells were treated with clonidine before virus infection and subjected to a virus replication assay with Rluc. Data are shown as means ± SEM of three independent experiments. (E) Effect of clonidine on NA activity. WSN/PB2-Rluc virus were mixed with the indicated compounds (zanamivir, 3 nM; clonidine, 10 µM), and the NA activity of the viruses was measured with the NA-Star kit. Data are shown as means ± SEM of five independent experiments.
